-
- Craig S. Anderson
- From the Clinical Trials Research Unit (C.A., K.C., M.H., V.F.), School of Population Health, Faculty of Medicine and Health Sciences, University of Auckland, New Zealand; The George Institute for International Health (C.A., K.C., M.H.), University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia; Neuroservices, Auckland City Hospital, and the Department of Medicine (P.A.B.), Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand; the Department of...
-
- Kristie N. Carter
- From the Clinical Trials Research Unit (C.A., K.C., M.H., V.F.), School of Population Health, Faculty of Medicine and Health Sciences, University of Auckland, New Zealand; The George Institute for International Health (C.A., K.C., M.H.), University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia; Neuroservices, Auckland City Hospital, and the Department of Medicine (P.A.B.), Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand; the Department of...
-
- Maree L. Hackett
- From the Clinical Trials Research Unit (C.A., K.C., M.H., V.F.), School of Population Health, Faculty of Medicine and Health Sciences, University of Auckland, New Zealand; The George Institute for International Health (C.A., K.C., M.H.), University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia; Neuroservices, Auckland City Hospital, and the Department of Medicine (P.A.B.), Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand; the Department of...
-
- Valery Feigin
- From the Clinical Trials Research Unit (C.A., K.C., M.H., V.F.), School of Population Health, Faculty of Medicine and Health Sciences, University of Auckland, New Zealand; The George Institute for International Health (C.A., K.C., M.H.), University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia; Neuroservices, Auckland City Hospital, and the Department of Medicine (P.A.B.), Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand; the Department of...
-
- P. Alan Barber
- From the Clinical Trials Research Unit (C.A., K.C., M.H., V.F.), School of Population Health, Faculty of Medicine and Health Sciences, University of Auckland, New Zealand; The George Institute for International Health (C.A., K.C., M.H.), University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia; Neuroservices, Auckland City Hospital, and the Department of Medicine (P.A.B.), Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand; the Department of...
-
- Joanna B. Broad
- From the Clinical Trials Research Unit (C.A., K.C., M.H., V.F.), School of Population Health, Faculty of Medicine and Health Sciences, University of Auckland, New Zealand; The George Institute for International Health (C.A., K.C., M.H.), University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia; Neuroservices, Auckland City Hospital, and the Department of Medicine (P.A.B.), Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand; the Department of...
-
- Ruth Bonita
- From the Clinical Trials Research Unit (C.A., K.C., M.H., V.F.), School of Population Health, Faculty of Medicine and Health Sciences, University of Auckland, New Zealand; The George Institute for International Health (C.A., K.C., M.H.), University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia; Neuroservices, Auckland City Hospital, and the Department of Medicine (P.A.B.), Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand; the Department of...
書誌事項
- 公開日
- 2005-10
- DOI
-
- 10.1161/01.str.0000181079.42690.bf
- 公開者
- Ovid Technologies (Wolters Kluwer Health)
この論文をさがす
説明
<jats:p> <jats:bold> <jats:italic>Background and Purpose—</jats:italic> </jats:bold> Long-term trends in stroke incidence in different populations have not been well characterized, largely as a result of the complexities associated with population-based stroke surveillance. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods—</jats:italic> </jats:bold> We assessed temporal trends in stroke incidence using standard diagnostic criteria and community-wide surveillance procedures in the population (≈1 million) of Auckland, New Zealand, over 12-month calendar periods in 1981–1982, 1991–1992, and 2002–2003. Age-adjusted first-ever (incident) and total (attack) rates, and temporal trends, were reported with 95% confidence intervals (CIs). Rates were analyzed by sex and major age groups. </jats:p> <jats:p> <jats:bold> <jats:italic>Results—</jats:italic> </jats:bold> From 1981 to 1982, stroke rates were stable in 1991–1992 and then declined in 2002–2003, to produce overall modest declines in standardized incidence (11%; 95% CI, 1 to 19%) and attack rates (9%; 95% CI, 0 to 16%) between the first and last study periods. Some favorable downward trends in vascular risk factors such as cigarette smoking were counterbalanced by increasing age and body mass index, and frequency of diabetes, in patients with stroke. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> There has been a modest decline in stroke incidence in Auckland over the last 2 decades, mainly during 1991 to 2003, in association with divergent trends in major risk factors. </jats:p>
収録刊行物
-
- Stroke
-
Stroke 36 (10), 2087-2093, 2005-10
Ovid Technologies (Wolters Kluwer Health)